



O 1 APR 11 2005 3:41PM BSKB COM

NO. 7445 P. 1

IFAN

650 Town Center Drive, Suite 620
Costa Mesa, CA 92626-1925
Phone: (714) 708-8555
Fax: (714) 708-8565

**Birch, Stewart,
Kolasch & Birch, LLP**

Fax

To:	Office of Patent Publications	From:	Leonard R. Svensson
Fax:	703-746-4000	Pages:	3 including cover sheet
Phone:		Date:	April 11, 2005
Your Ref.:	Application No. 09/806,703	Our Ref.:	4614-0107
Re:	Summary of Interview	CC:	
<input type="checkbox"/> Urgent <input type="checkbox"/> For Review <input type="checkbox"/> Please Comment <input type="checkbox"/> Please Reply <input type="checkbox"/> Please Recycle			

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. If your receipt of this transmission is in error, please notify this firm immediately by collect call to (714) 708-8555, and send the original transmission to us by return mail at the address above.

• **Comments:**



APR 11 2005 3:41PM BSKB COM

NO. 7445 P. 2

PATENT
4614-0107P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: STEINAA, Lucilla t al. Conf.: 5928
Appl. No.: 09/806,703 Group: 1644
Filed: April 30, 2001 Examiner: DIBRINO, M.
For: NOVEL METHODS FOR THERAPEUTIC
VACCINATION

SUMMARY OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 11, 2005

Sir:

In response to the Notice of Allowability issued on March 31, 2005, the following remarks are respectfully submitted in connection with the above-identified application.

Applicants' representative participated in a telephonic interview with Examiner Marianne DiBrino on January 6, January 28, March 7 and March 14, 2005. All of the pending claims were discussed and the interviews resulted in claims 69, 86, 89, 92 and 95 being allowed.

During the course of the interviews, the preservation of the epitopes of the extracellular part of Her2 and introduction of T-helper epitopes at a number of selected positions was discussed. These discussions led to the amendment of claim 69 to its final form. In addition, claim 89 and claim 92 were amended to include a Markush group. Finally, the Fidel Zavala et al. reference was discussed. This reference provides evidence that "P. falciparum

Appl. No. 09/806,703

CS," as recited in instant claim 92, was a term known in the art at the time the invention was made and which is equivalent to "P. falciparum circumsporozoite."

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17, particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, L.P.

47,604

By Leonard S. Svensson #30 330

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

LRS/SWG/sbp
4614-0107P

~~I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450, on: April 11, 2015~~ (Date of Deposit)

~~BIRCH, STEWART, KOLASCH & BIRCH, LLP~~

BRUNNEN

Dale B. King

Certificate of Transmission
I hereby Certify that this correspondence is being
facsimile transmitted to the Patent and
Trademark Office: *[Signature]*

On April 11, 2005 Date
Janice B. Pace Signature
Janice B. Pace
Typed or printed name of person signing certificate